Daily Archives: May 20, 2022 | LinksMedicus Free Medical News & Perspectives

AHA Scientific Statement: Preventing and managing falls in adults with cardiovascular disease.

20 May, 2022 | 11:20h | UTC

Preventing and Managing Falls in Adults With Cardiovascular Disease: A Scientific Statement From the American Heart Association – Circulation: Cardiovascular Quality and Outcomes

News Release: Statement addresses ways to prevent heart-related risks for falling – American Heart Association

Commentary: AHA News: Falls Can Be a Serious, Poorly Understood Threat to People With Heart Disease – HealthDay

WHO: 2022 Progress report on the Global Action Plan for Healthy Lives and Well-being for All.

20 May, 2022 | 11:17h | UTC

2022 Progress report on the Global Action Plan for Healthy Lives and Well-being for All – World Health Organization

Full Report: Stronger collaboration for an equitable and resilient recovery towards the health-related Sustainable Development Goals, incentivizing collaboration – World Health Organization

Commentary on Twitter (thread – click for more)

Progress on the health-related SDGs is further off track – countries have achieved only about one-fourth of what is needed to achieve the SDG health targets by 2030: Global Action Plan for Healthy Lives & Well-being for All #SDG3GAP progress report.

More https://t.co/HF8LO5UbVo pic.twitter.com/kGXoMTHnnh

— World Health Organization (WHO) (@WHO) May 18, 2022

WHO validates 11th vaccine for COVID-19.

20 May, 2022 | 11:16h | UTC

WHO validates 11th vaccine for COVID-19 – World Health Organization

Commentary on Twitter

WHO issued an emergency use listing for CONVIDECIA, a vaccine manufactured by CanSino Biologics, China, adding to a growing portfolio of #COVID19 vaccines validated by WHO https://t.co/QdpHiasT2p pic.twitter.com/2B54FwiNDl

— World Health Organization (WHO) (@WHO) May 19, 2022

Covid-19: Second boosters may benefit at-risk groups but have “minimal” impact for others, says WHO.

20 May, 2022 | 11:08h | UTC

Covid-19: Second boosters may benefit at-risk groups but have “minimal” impact for others, says WHO – The BMJ

Original Statement: Interim statement on the use of additional booster doses of Emergency Use Listed mRNA vaccines against COVID-19 – World Health Organization

Related recommendations:

COVID-19: Joint statement from ECDC and EMA on the administration of a fourth dose of mRNA vaccines –
European Centre for Disease Prevention and Control

Coronavirus (COVID-19) Update: FDA Authorizes Second Booster Dose of Two COVID-19 Vaccines for Older and Immunocompromised Individuals – U.S. Food & Drug Administration

COVID-19 evidence: a Cochrane round-up.

20 May, 2022 | 11:14h | UTC

COVID-19 evidence: a Cochrane round-up – Cochrane Library

Systematic Review: Thoracic imaging tests for the diagnosis of COVID‐19.

20 May, 2022 | 11:13h | UTC

Thoracic imaging tests for the diagnosis of COVID‐19 – Cochrane Library

Summary: How accurate is chest imaging for diagnosing COVID-19? – Cochrane Library

M-A: Antibiotic duration for community acquired pneumonia in outpatient children in high-income countries – treatment duration of 3–5 days is equally effective and safe vs. 7–10 days.

20 May, 2022 | 11:10h | UTC

Antibiotic treatment duration for community acquired pneumonia in outpatient children in high-income countries – a systematic review and meta-analysis – Clinical Infectious Diseases

Antibiotics for Pediatric Pneumonia: Might Less Be Enough? – Annals of Emergency Medicine

Effect of Amoxicillin Dose and Treatment Duration on the Need for Antibiotic Re-treatment in Children With Community-Acquired Pneumonia: The CAP-IT Randomized Clinical Trial – JAMA

Extended Versus Standard Antibiotic Course Duration in Children <5 Years of Age Hospitalized With Community-acquired Pneumonia in High-risk Settings: Four-week Outcomes of a Multicenter, Double-blind, Parallel, Superiority Randomized Controlled Trial – The Pediatric Infectious Disease Journal

Short- vs Standard-Course Outpatient Antibiotic Therapy for Community-Acquired Pneumonia in Children: The SCOUT-CAP Randomized Clinical Trial – JAMA Pediatrics

Appropriate Use of Short-Course Antibiotics in Common Infections: Best Practice Advice From the American College of Physicians – Annals of Internal Medicine

Short-Course Antimicrobial Therapy for Pediatric Community-Acquired Pneumonia: The SAFER Randomized Clinical Trial – JAMA Pediatrics

Efficacy of short-course antibiotic treatments for community-acquired pneumonia in adults: A systematic review and meta-analysis – Antimicrobial Agents and Chemotherapy

Commentary on Twitter

Antibiotic treatment duration for community acquired pneumonia in outpatient children in high-income countries – a systematic review and meta-analysis https://t.co/HxKywgCiXS
A short AB treatment of 3–5 days was equally effective and safe compared to the longer – 7–10 days

— Dr. Alex 💊🩺🎮 (@DrAlexxx78) May 17, 2022

Cytomegalovirus blood reactivation in COVID-19 critically ill patients: risk factors and impact on mortality.

20 May, 2022 | 11:06h | UTC

Cytomegalovirus blood reactivation in COVID-19 critically ill patients: risk factors and impact on mortality – Intensive Care Medicine

Commentary on Twitter

CMV reactivation in #COVID19 critically ill pts:
🦠frequent! >20% in this study
🧪risk depends on severity of illness/occurrence of secondary bacterial infections in #ICU
🏥 prolonged hospital stay & higher mortality but independent association lacking.
📎 https://t.co/N8JVD1GyPQ pic.twitter.com/KYRtLmxtJg

— Intensive Care Medicine (@yourICM) May 18, 2022

SCAI guidelines for the management of patent foramen Ovale.

20 May, 2022 | 11:01h | UTC

SCAI Guidelines for the Management of Patent Foramen Ovale – JSCAI

Editorial: New SCAI Guidelines: Trying to Close the Holes in the PFO Literature – JSCAI

Commentary: PFO Closure Guidelines Address Older Adults, Trial-Excluded Groups— Document acknowledges skimpy evidence – MedPage Today (free registration required)

Advances in the management of cardioembolic stroke associated with patent foramen ovale – The BMJ

Practice advisory update summary: Patent foramen ovale and secondary stroke prevention: Report of the Guideline Subcommittee of the American Academy of Neurology – Neurology

Heterogeneity of Treatment Effects in an Analysis of Pooled Individual Patient Data From Randomized Trials of Device Closure of Patent Foramen Ovale After Stroke – JAMA (link to abstract – $ for full-text)

Management of the Patient With Patent Foramen Ovale in 2021: A Spectrum of Cases – Mayo Clinic Proceedings

RCT: Apixaban is not superior to the standard of care (vitamin K antagonist or antiplatelet therapy if anticoagulation is indicated or not, respectively) after transcatheter aortic valve implantation.

20 May, 2022 | 10:59h | UTC

Apixaban vs. standard of care after transcatheter aortic valve implantation: the ATLANTIS trial – European Heart Journal (link to abstract – $ for full-text)

Editorial: Defining optimal antithrombotic therapy post-TAVI: the contribution of ATLANTIS – European Heart Journal

Edoxaban versus Dual Antiplatelet Therapy for Leaflet Thrombosis and Cerebral Thromboembolism after TAVR: The ADAPT-TAVR Randomized Clinical Trial – Circulation

Comparing Single- and Dual-Antiplatelet Therapies After Transcatheter Aortic Valve Implantation – The Annals of Thoracic Surgery

Aspirin Alone Versus Dual Antiplatelet Therapy After Transcatheter Aortic Valve Implantation: A Systematic Review and Patient‐Level Meta‐Analysis – Journal of the American Heart Association

Aspirin with or without Clopidogrel after Transcatheter Aortic-Valve Implantation – New England Journal of Medicine

Anti-Thrombotic Strategy to Lower All cardiovascular and Neurologic Ischemic and Hemorrhagic Events after Trans-Aortic Valve Implantation for Aortic Stenosis – ATLANTIS – American College of Cardiology

Variation in the estimated prevalence of multimorbidity: systematic review and meta-analysis of 193 international studies.

20 May, 2022 | 10:58h | UTC

Variation in the estimated prevalence of multimorbidity: systematic review and meta-analysis of 193 international studies – BMJ Open

Commentary on Twitter

Our meta-analysis led by Iris Szu-Szu & Bruce Guthrie

Prevalence of multimorbidity = 42.4%

No difference in prevalence between low-income or middle-income countries

Future studies should use a common core conditions to improve comparabilityhttps://t.co/FdjJ2P4dtN pic.twitter.com/DP3IeWI5sR

— Prof Kamlesh Khunti (@kamleshkhunti) May 19, 2022

RCT: Elacestrant (oral selective estrogen receptor degrader) vs. standard endocrine therapy for estrogen receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer.

20 May, 2022 | 10:55h | UTC

Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial – Journal of Clinical Oncology

Commentary: EMERALD Trial: Oral Selective Estrogen Receptor Degrader as Second- or Third-Line Therapy for Advanced Breast Cancer – The ASCO Post

M-A: Comparison of Amitriptyline with other FDA–approved treatments for fibromyalgia.

20 May, 2022 | 10:49h | UTC

Comparison of Amitriptyline and US Food and Drug Administration–Approved Treatments for Fibromyalgia: A Systematic Review and Network Meta-analysis – JAMA Network Open

M-A: Management of asymptomatic severe aortic stenosis.

20 May, 2022 | 10:54h | UTC

Management of asymptomatic severe aortic stenosis: a systematic review and meta-analysis – openheart

Commentaries on Twitter

Management of asymptomatic severe aortic stenosis: a systematic review and meta-analysis @justvick @vass_vassiliou @MarcDweck @jhfrudd https://t.co/eFJbT3AiPn pic.twitter.com/g2GwKvlODW

— Open Heart (@Open_HeartBMJ) May 18, 2022

Our latest work led by #WIC @justvick on earlier surgery in asymptomatic aortic stenosis @Open_HeartBMJ inc all RCT & observational studies – huge suggestion that ‘earlier the better!’ https://t.co/u56LffOjAD great collaboration with @MarcDweck @jhfrudd @HEARTinMagnet #epeeps pic.twitter.com/WlKn1e6c9S

— Vass Vassiliou (@vass_vassiliou) May 18, 2022

Age distribution of all-cause mortality among children younger than 5 years in low- and middle-income countries.

20 May, 2022 | 10:46h | UTC

Age Distribution of All-Cause Mortality Among Children Younger Than 5 Years in Low- and Middle-Income Countries – JAMA Network Open

Association of extreme heat with all-cause mortality in the contiguous US, 2008-2017.

20 May, 2022 | 10:48h | UTC

Association of Extreme Heat With All-Cause Mortality in the Contiguous US, 2008-2017 – JAMA Network Open

Commentary on Twitter

1/ Out now in @JAMANetworkOpen. @petegroen
@rm_werner and I demonstrate the association between extreme heat days and all-cause mortality across the contiguous US.@PennLDI https://t.co/s6rPMN7qUD

— Sameed Khatana, MD MPH (@SameedKhatana) May 19, 2022